| Literature DB >> 36186264 |
Sai Deepika Ram Mohan1, Kurpad N Shashidhar1, Raveesha Anjanappa2, Muninarayana Chandrappa3.
Abstract
Objective Prevalence of type-2 diabetes mellitus (DM) and diabetic nephropathy is growing rapidly in Asian countries, affecting low- and middle-income groups. One of the epidemiological issues of Kolar district is fluorosis; advanced glycation end product, carboxymethyl lysine (CML), and a molecule of interest Sirtuin1 are employed in the present study. In the correlation of fluoride with sirtuin1and CML with sirtuin1 of cases lies the important rationale of the study to assess the extent of kidney damage. Materials and Methods This is a comparative cross-sectional study with three groups, each with 70 patients, as follows: G1, control; G2, diabetes with diabetic nephropathy; and G3, type-2 DM without any complications. Informed written consent was obtained from all study patients. All the routine investigations were performed by fully automated Vitro 5, 1 Fs, Vitros. Fasting insulin was analyzed by Vitro eCI and glycated hemoglobin was estimated by BioRad D10. Sirtuin1, CML, and fructosamine were estimated by double antibody sandwich technique. Statistical Analysis The statistical analysis was performed by SPSS 20 (IBM) software. Means of normally distributed data were compared using analysis of variance (ANOVA), and not normally distributed data were compared by Kruskal-Wallis test. A p -value of less than 0.05 was considered statistically significant. Results A decrease in sirtuin1, serum, and urine fluoride of group 2 (34.74 [25.08-53.2], 0.24 [0.2-0.5], and 0.24 [0.16-0.41]) was observed compared with other groups. Increased CML and fluoride act as prooxidant, restricting the effect of sirtuin1 on cellular damage, causing further complications such as increased insulin resistance and decreased insulin sensitivity. Conclusion The alterations in serum sirtuin1 levels indicate the severity of damage due to stress during hyperglycemia and fluoride toxicity; hence, sirtuin1 can be considered as biomarker of aging. Subsequently, the correlation of CML, estimated glomerular filtration rate (eGFR), and fluoride with sirtuin1 indicates that increasing sirtuin1 may defend the forthcoming damage and could be considered in therapeutics. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: carboxymethyl lysine; fluoride; sirtuin1; therapeutics; type-2 diabetes mellitus
Year: 2021 PMID: 36186264 PMCID: PMC9519268 DOI: 10.1055/s-0041-1732817
Source DB: PubMed Journal: J Lab Physicians ISSN: 0974-2727
Demographic and biochemical parameters of all three groups
| Parameter |
Group 1 (
|
Group 2 (
|
Group 3 (
| |
|---|---|---|---|---|
|
| ||||
| Age (y) | 42.71 ± 9.2 | 56. 04 ± 8.2 | 53.1 ± 8.2 | < 0.001 |
| SBP (mm Hg) | 122.1 ± 5.4 | 137.6 ± 17.6 | 125.3 ± 11.02 | < 0.001 |
| DBP (mm Hg) | 78.3 ± 4.6 | 87.53 ± 11.2 | 82.23 ± 7.64 | < 0.001 |
| BMI (kg/m 2 ) | 24.1 ± 3. | 22.6 ± 1.6 | 23.2 ± 1.83 | < 0.001 |
|
| ||||
| FBS (mg/dL) | 93.94 ± 9.4 | 173.6 ± 64.02 | 182.3 ± 67.7 | < 0.001 |
| PPBS (mg/dL) | 115.1 ± 16.2 | 271.2 ± 91 | 273.1 ± 103 | < 0.001 |
| HbA1c (%) | 5.5 ± 0.5 | 8.2 ± 2 | 9.2 ± 2.4 | < 0.001 |
|
| ||||
| Blood urea (mg/dL) | 19.6 ± 6.6 | 69.03 ± 27.5 | 27.6 ± 13.4 | < 0.001 |
| Serum creatinine (mg/dL) | 0.66 ± 0.1 | 3.4 ± 1.5 | 0.68 ± 0.21 | < 0.001 |
| Uric acid (mg/dL) | 4.4 (3.7–5.8) | 4.0 (2.6–5.6) | 4.0 (3.07–5.1) | 0.023 |
| Serum albumin (g/dL) | 4.05 ± 0.4 | 2.8 ± 0.8 | 4.3 ± 0.9 | < 0.001 |
| Sodium (mEq/L) | 137 ± 2.1 | 133.5 ± 5.1 | 135.8 ± 3.2 | < 0.001 |
| Potassium (mEq/L) | 4.3 ± 0.41 | 4.6 ± 0.9 | 4.4 ± 0.5 | 0.016 |
|
| ||||
| Total cholesterol (mg/dL) | 171.4 ± 39.1 | 157.6 ± 59.6 | 183.3 ± 59.6 | 0.007 |
| Triglycerides (mg/dL) | 141 (93–193.5) | 148 (114.5–211) | 184 (119.5–215.5) | 0.033 |
| HDL (mg/dL) | 39.3 ± 10.1 | 28.3 ± 10.3 | 40.9 ± 13.7 | < 0.001 |
| LDL (mg/dL) | 98 (76.2–122) | 87 (50.7–110.5) | 104 (86.8–127.3) | 0.01 |
| VLDL (mg/dL) | 28 (17.7–36.4) | 30 (23–42.2) | 36.9 (24–43.1) | 0.020 |
| nHDL (mg/dL) | 132.1 ± 39.5 | 125.7 ± 58.9 | 145.4 ± 56.8 | 0.077 |
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; FBS, fasting blood sugar; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; nHDL, non–high density lipoprotein; PPBS, post- prandial blood sugar; SBP, systolic blood pressure; VLDL, very low density lipoprotein.
Special parameters
| Parameters |
Group 1 (
|
Group 2 (
|
Group 3 (
| |
|---|---|---|---|---|
| Sirtuin1 (ng/mL) | 46.76 (12.4–97) | 34.74 (25.08–53.2) | 49.6 (33.71–101.63) | 0.002 |
| Serum fluoride (ppm) | 0.66 (0.62–0.72) | 0.24 (0.2–0.5) | 0.6 (0.56–0.68) | < 0.001 |
| Urine fluoride (ppm) | 0.89 (0.55–1.49) | 0.24 (0.16–0.41) | 0.72 (0.53–1.02) | < 0.001 |
| CML (ng/mL) | 899 (625.25–1,306.5) | 1,815 (1,100–2,591.13) | 1,870 (1,155.1–2,272.5) | < 0.001 |
Abbreviations: CML, carboxymethyl lysine; ppm, parts per million.
Extended diabetic profile
| Parameters |
Group 1 (
|
Group 2 (
|
Group 3 (
| |
|---|---|---|---|---|
| Fructosamine (ng/mL) | 100.2 (55.8–172.4) | 245.93 (0.16–0.41) | 329.9 (131.42–88.2) | < 0.001 |
| Insulin (μIU/mL) | 9.9 (6.22–14.4) | 8.82 (5.14–13.32) | 9.11 (6.35–15.62) | 0.370 |
| HOMA-IR | 2.34 (1.3–3.2) | 3 (1.99–5.62) | 4.35 (2.4–7.1) | < 0.001 |
| QUICKI | 0.34 ± 0.02 | 0.32 ± 0.03 | 0.3 (0.29–0.34) | < 0.001 |
Abbreviations: HOMA-IR, homeostasis model assessment–insulin resistance; QUICKI, quantitative insulin check index.
Extended renal profile
| Parameters |
Group 1 (
|
Group 2 (
|
Group 3 (
| |
|---|---|---|---|---|
| Cystatin C (mg/L) | 0.9 (0.69–1.2) | 4.3 (3–6.5) | 2.3 (1.46–3.69) | < 0.001 |
| eGFR (mL/min/1.73 m 2 ) | ||||
|
CKD-EPI 2009
| 109.5 (99–116.25) | 26 (17.75–37.25) | 106 (93–115.5) | < 0.001 |
|
CKD-EPI 2012
| 92.5 (74–118.5) | 60.5 (40–91) | 118.5 (95.75–137.25) | < 0.001 |
Abbreviation: eGFR, estimated glomerular filtration rate; CKD-EPI, chronic kidney disease-epidemiology.
Equation based on creatinine.
Equation based on creatinine and cystatin C.
Correlation of serum fluoride and CML with sirtuin1
| Parameters |
Group 1 (
|
Group 2 (
|
Group 3 (
|
|---|---|---|---|
|
Spearman's rho (
| |||
| Serum fluoride (ppm) | 0.061 | 0.292 | 0.005 |
| CML (ng/mL) | 0.188 | 0.054 | 0.153 |
Abbreviations: CML, carboxymethyl lysine; ppm, parts per million.
Correlation of HOMA-IR and QUICKI with sirtuin1
| Parameters |
Group 1 (
|
Group 2 (
|
Group 3 (
|
|---|---|---|---|
|
Spearman's rho (
| |||
| HOMA-IR | 0.028 | +0.047 | +0.073 |
| QUICKI | +0.098 | 0.004 | +0.022 |
Abbreviations: HOMA IR, homeostasis model assessment–insulin resistance; QUICKI, quantitative insulin sensitivity check index.
Fig. 1Correlation of serum and urine fluoride with eGFR in group 1 (healthy controls). G1SF, group 1 serum fluoride; G1UF, group 1 urine fluoride; G1eGFR, group 1 estimated glomerular filtration rate.
Fig. 2Correlation of serum and urine fluoride with eGFR in group 2 (diabetic nephropathy). G2SF, group 2 serum fluoride; G2UF, group 2 urine fluoride; G2eGFR, group 2 estimated glomerular filtration rate.
Fig. 3Correlation of serum and urine fluoride with eGFR in group 3 (type-2 DM). DM, diabetes mellitus; G3SF, group 3 serum fluoride; G3UF, group 3 urine fluoride; G3eGFR, group 3 estimated glomerular filtration rate.